
Ultra-High Concentration Nitric Oxide (UNO) Enhances Anti-CTLA-4 Treatment Activity and Induces a Durable Anti-Tumor Immune Response

Next level immuNO-oncology

Yogev Sela¹, Matan Goldshtein¹, Jedidiah M. Monson², Hila Confino¹, Matt Johnson², Selena Chaisson², Amir Avniel^{3,4}, Mark D. Pegram⁵ ¹Beyond Cancer, Rehovot, Israel ²Beyond Cancer, Atlanta, GA, USA ³Beyond Air, Garden City, NY, USA ⁴Beyond Air, Rehovot, Israel ⁵Stanford University, Stanford, CA, USA

> AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS October 11-15, 2023




Tumor T-cell Response Following UNO and Anti-mCTLA-4


CD8+ cytotoxic T-cells (Figure 3A) and CD4+ helper T-cells (Figure 3B) are elevated in the tumor at day 5 post-treatment. In addition, more T-helper cells are active following UNO and anti-mCTLA-4 treatment as seen by IFNX upregulation (Figure 3C).


B. CD4+ T-cells, Ki-67^{high} A. CD8+ T-cells UNO anti-mCTLA-4 UNO+ UNO anti-mCTLA-4 UNO+ C. T-helpers, IFNX+ UNO Anti-mCTLA-4 UNO+ Untreated Anti-mCTI A-4 Figure 3: Tumor T-cell Levels Following UNO and Anti-mCTLA-4

Treatment at Day 5. (A) Tumor T-cytotoxic cells (B) Proliferating Tumor T-helper cells, (C) IFNX+ expressing tumor T-helper cells.

The immunodominant AH-1 antigen is associated with anti-tumor immune response to CT26 tumors. A systemic antigen-specific and central memory (CM) response is observed by day 7 (Figure 4A and 4B). Durable upregulation in systemic AH-1-specific T-cells is observed in cured mice at day 55 (Figure 4C) and day 100 (Figure 4D).







Conclusions

Intratumorally, at day 5 post-UNO treatment, T-helper and T-cytotoxic cells are significantly increased in the combination arm relative to the anti-mCTLA-4 arm alone. Systemically, UNO stimulates a significantly higher central memory T-cell response than anti-mCTLA-4 and synergizes with this drug by day 7 to generate a higher antigenspecific T-cell response. Durable upregulation in systemic AH-1-specific T-cells is still seen at day 55 post-therapy and has been confirmed as late as day 100. A clinical study investigating intratumoral administration of UNO has been initiated (BA-ONC-01 clinicaltrials.gov NCT identifier: NCT05351502).

BEYOND CANCER™

Systemic T-cell Response Following UNO and Anti-mCTLA-4

Treatment at Days 7, 55, and 100. (A) Blood AH-1 T-cells at day 7, (B) Blood CM T-cells at day 7, (C,D) Blood AH-1-specific T-cells (Left), and mouse survival (Right) at day 55 and 100. *p<0.05, **p<0.01